Patent Application
20140315938
The present invention relates to a combination therapy for the treatment of food addiction, obesity, binge eating disorder, or binge eating behavior.
The present invention is directed to a combination treatment of an mu-opioid receptor antagonist and GABA B receptor agonist and, optionally a third therapeutic agent selected from CB-1 receptor antagonists, glycine reuptake inhibitors, dopamine augmenting compounds, nicotine receptor agonists, psychostimulants, mGlu2/3 agonists, mGlu5 antagonists, glycine-site partial agonists, cystine-glutamate exchangers, cystine-glutamate activators, glutamate transporter inhibitors, mGlu5 receptor agonists or NMDA receptor co-agonists for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. Specific combinations of these classes of compounds are provided in Table 1. Tables 2-3 provide exemplary combinations of specific compounds suitable for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25 or having a BMI between 25 and 35); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. The invention may also be used for individuals who have difficulty in controlling the amounts of fast foods consumed during a given period of time.
FIG. 1—Baclofen (alone) has no effect on binge eating of sugar.
FIGS. 2A-2B—Baclofen (alone) reduces intake of oil-containing palatable foods.
FIGS. 3A-3C—Naltrexone has a trend toward reducing food intake in the oil containing groups, but has no effect on sugar-bingeing rats.
The present invention is directed to a combination treatment of an mu-opioid receptor antagonist and GABA B agonist and, optionally a third therapeutic agent selected from CB-1 receptor antagonists, glycine reuptake inhibitors, dopamine augmenting compounds, nicotine receptor agonists, psychostimulants, mGlu2/3 agonists, mGlu5 antagonists, glycine-site partial agonists, cystine-glutamate exchangers, cystine-glutamate activators, glutamate transporter inhibitors, mGlu5 receptor agonists or NMDA receptor co-agonists for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. Specific combinations of these classes of compounds are provided in Table 1. Tables 2-3 provide exemplary combinations of specific compounds suitable for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25 or having a BMI between 25 and 35); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. The invention may also be used for individuals who have difficulty in controlling the amounts of fast foods consumed during a given period of time.
The term “combination” as in the phrase “a first compound in combination with a second compound” includes co-administration of a first therapeutically effective compound and a second therapeutically effective compound, which for example, may be dissolved or intermixed in the same pharmaceutically acceptable carrier. The term “concurrently administered” when referring to the various compounds disclosed herein indicates that the compounds can be administered separately at the same time or sequentially in any order at different points in time. The compounds, however, should be administered close in time so as to provide an effect suitable for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. Typically, concurrently administered compounds are administered within 60 minutes of one another.
The term “synergistic effect” as used herein refers to the combined effect of administering two (or three) therapeutic compounds where the overall response is greater than the sum of the two individual effects (e.g., the effects observed when each compound is administered alone as a monotherapy).
The dosage of the individual therapeutic compounds that are to be administered to individuals may be adjusted to provide the optimal therapeutic response. Thus, the specific dose level for any particular patient may vary depending upon a variety of factors, including but not limited to, the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. The considerations for determining the proper dose levels are well known in the art.
In one embodiment, naltrexone is coadministered or administered in combination with baclofen and, optionally additional therapeutic compounds. In certain cases, naltrexone, in an amount of about 25 to 100 milligrams per day, and baclofen, in an amount ranging between about 15 and about 120 milligrams per day (preferably between about 20 milligrams and about 80 milligrams per day) can be administered in combination or coadministered. As set forth in the Tables, a combination of three therapeutic compounds can be used in the disclosed methods. For example, a combination of naltrexone, baclofen and acamprosate or buproprion (or buproprion (extended release) can be coadministered or administered in combination to a subject according to the disclosed methods. In such embodiments, naltrexone, in an amount of about 25 to 100 milligrams per day, baclofen, in an amount ranging between about 15 and about 120 milligrams per day (preferably between about 20 milligrams and about 80 milligrams per day), and acamprosate in an amount of between about 300 and 2500 milligrams per day (e.g., as two 333-mg tablets taken three times a day) can be coadministered or administered in combination. Alternatively, naltrexone, in an amount of about 25 to 100 milligrams per day, baclofen, in an amount ranging between about 15 and about 120 milligrams per day (preferably between about 20 milligrams and about 80 milligrams per day), and buproprion (or buproprion extended release) in an amount of between 75 milligrams and 450 milligrams per day (or, preferably, between about 150 and about 300 milligrams per day) can be coadministered or administered in combination within the disclosed methods. Other combinations of therapeutic compounds and compositions according to the invention are set forth in Tables 2 and 3.
The therapeutic compounds used in the disclosed combination therapies can be administered in oral forms. These include, but are note limited to, tablets, capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Rapid-release and time-controlled release (extended release) formulations of the disclosed therapeutic compounds can be used for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. The therapeutic compounds disclosed herein can, typically, be administered in “pharmaceutically acceptable carriers such as pharmaceutical diluents, pharmaceutical excipients or pharmaceutical carriers. For instance, tablets or capsules can comprise one or more of the disclosed therapeutic compounds and lactose, starch, sucrose, glucose, modified sugars, modified starches, methyl cellulose and its derivatives, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and other reducing and non-reducing sugars, magnesium stearate, steric acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate and the like. Liquid formulations can comprise one or more therapeutic agent in combination with ethanol, glycerol, water and the like. Additionally, the compositions can contain binders, lubricants, disintegrating agents, coloring and/or flavoring agents as desired.
In the context of the present invention, the term “individual” refers to a mammal. In particular embodiments, the mammal can be a rodent, such as a mouse or rat. In other embodiments, the mammal is a human. Individuals to whom the methods disclosed herein can be applied can be identified by a variety of means, including the use of body mass index (BMI) or surveys that identify individuals exhibiting symptoms of food addiction (e.g., the Yale Food Addiction Scale (see
Thus, certain aspects of the disclosed invention provide methods for the treatment of individuals who meet the definition of food addiction; individuals that are overweight or obese (e.g., a BMI≧25); individuals that have a binge eating disorder; or individuals who engage in a binge eating behavior. These methods comprise the administration of a composition as set forth in any one of Tables 1-3 to an individual meeting the definition of food addiction, an individual who is obese or overweight, an individual who has a binge-eating disorder or individuals who engage in binge eating behavior in amounts effective to control or reduce the intake of food. In preferred embodiments of this aspect of the invention, the foods are fatty foods, sugar rich foods, or foods that are both fatty and sugar-rich.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.
Drugs (2 doses/drug)
Balcofen (at 1.0 and 1.8 mg/kg, administered i.p.)
Naltrexone (at 0.1 and 1.0 mg/kg, administered i.p.)
Baclofen+naltrexone (mixed low and mixed high)
Saline
Groups (n=10/group)
1. Binge sugar (10% sucrose solution, w/v)
2. Binge Fat (35% oil emulsion, w/v)
3. Binge Sweet/Fat (10% sucrose, 35% oil emulsion, w/v)
Procedure
Groups of animals (rats) were maintained on their diets for 3 weeks to establish stable binge eating behavior. After this period of time, the rats were administered three days of daily i.p. injections of saline (to acclimate to the injection procedure), and sugar/chow intake was measured after the first hour of access and then hourly for the next 3 hours, as well as at the end of the 12-h access period. After this three day period, rats were given baclofen+naloxone, and measurements taken as described above. Other dosage amounts of baclofen and naloxone were tested, as were the effects of these compounds alone (with measurements being performed as described above). Vehicle injections were performed between the various tests in order to allow for suitable clearance of compounds from the animals. Interestingly, the effect of baclofen/naltrexone on suppressing palatable food intake is specific to palatable food (fatty foods, sweet foods or foods choices that were both fatty and sweet, see
Male Sprague-Dawley rats, 250-300 g at the onset of the experiment, were obtained from Taconic Farms (Germantown, N.Y., USA). Rats were housed individually on a 12-h reversed light/dark cycle and given 1 wk to acclimate before diet training began.
The rats were divided into groups (n=10/group) matched for body weight and assigned to one of the following dietary conditions: (1) Binge Sugar, (2) Binge Fat or (3) Binge Sugar-Fat. All rats received palatable diets and standard rodent chow (LabDiet #5001, PMI Nutrition International, Richmond, Ind., USA; 10% fat, 20% protein, 70% carbohydrate, 3.02 kcal/g) for 12 h/day, starting 4 h after the onset of the dark cycle. Water was available ad libitum.
All palatable foods were mixed in the laboratory. The Binge Sugar group had access to a 10% (w/v) sucrose solution (Domino® Granulated Pure Cane Sugar, dissolved in tap water, 0.4 kcal/mL). The Binge Fat group had access to a 35% (w/v) fat emulsion (3.1 kcal/mL) and the Binge Sugar-Fat group had access to a 10% (w/v) sugar solution and 35% (w/v) fat emulsion (3.5 kcal/mL). Both emulsions were made with Wesson® Pure Vegetable Oil in tap water and 0.6% (w/v) Emplex, a commercially available emulsifier (American Ingredients Company, Kansas City, Mo., USA). Palatable food intakes were recorded daily. Chow intake was recorded weekly. Body weights were taken at the beginning and end of the 21-day diet period.
After 21 days on these diets, drug testing began. During testing, diet regimens were maintained. Approximately 3.5 h into the dark cycle, animals were weighed and intraperitoneal (i.p.) injections of drug were given (according to the schedule below). 30-min later (4 h into the dark cycle) palatable food and chow were made available to the rats. For the first 3 days, rats were acclimated to handling and injections with daily vehicle injections (0.9% saline, Lakeforest, Ill., USA, Hospira, i.p. 1 mL/kg). For days 4-16 of drug testing, either vehicle or drug was alternatively administered, starting with drug on day 4. Drug injections included combinations of R-baclofen (Tocris, Ellisville, Mo., USA) and naltrexone hydrochloride (Sigma, St. Louis, Mo., USA); 0.1 mg/kg naltrexone and 1.0 mg/kg baclofen, or 1.0 mg/kg naltrexone and 1.8 mg/kg baclofen. Or, either drug was tested alone: 0.1 and 1.0 mg/kg naltrexone, or 1.0 and 1.8 mg/kg baclofen. Intake of palatable food and chow was measured hourly after injection for 4 h and again at the end of the 12-h access period.
Palatable food and standard chow intakes following saline injections between days 4-16 were averaged. All data were analyzed using one-way ANOVAs with post hoc Multiple Comparisons, when appropriate. In Tables 4-7, values having the same letter superscript are statistically different from one another.
At the beginning of the study, the groups were weight-matched [F(2,29)≦0.001, 6 p=n.s.; 280.0±3.6 g (Binge Sugar), 280.1±3.4 g (Binge Fat), 280.0±3.6 g (Binge Sugar-Fat)]. There was still no difference in body weight among groups after 21 days on their respective diets [F(2,29)=0.39, p=n.s.; 387.2±7.2 g (Binge Sugar), 396.7±5.7 g (Binge Fat), and 393.83±10.0 g (Binge Sugar-Fat)], or at the completion of injections [F(2,29)=1.68, p=n.s.; 419.9±9.3 g (Binge Sugar), 442.4±6.5 g (Binge Fat), 438.3±11.2 g (Binge Sugar-Fat)].
Table 4 shows a summary of palatable food intake in response to the drugs tested as a percent of each groups' saline injections. Naltrexone significantly decreased 1 h (F(2,29)=3.66, p<0.05, Table 5) and 12-h intake in the Binge Sugar group (F(2,29)=5.94, p<0.01), with the greatest suppression of intake seen following the higher dose (p<0.05). Similar to previous reports {Berner, 2009 #597; Corwin, 2009 #607}, there was no effect of baclofen on sugar intake at 1 h (F(2, 29)=0.79, p=n.s.) or at 12 h (F(2,29)=0.13, p=n.s.). The combination of naltrexone and baclofen decreased sugar intake at 1 h (F(2,29)=4.067, p<0.05), with the strongest suppression seen at the high-dose combination (p<0.05). However, this effect was not apparent at 12 h (F(2,29)=0.28, p=n.s.).
For the Binge Fat group, there was no significant effect of naltrexone at 1 h (F(2,29)=2.55, p=n.s.) or 12 h (F(2,29)=0.96, p=n.s.). Baclofen decreased fat intake at 1 h (F(2,29)=6.85, p<0.01) and 12 h (F(2,29)=8.15, p<0.01), with the strongest suppression seen following the higher dose (p<0.01). The combination of naltrexone and baclofen also decreased fat intake at 1 h (F(2,29)=12.11, p<0.0001) and 12 h 7 (F(2,29)=8.41, p<0.01), again with the strongest suppression seen following the high-dose combination (p<0.01).
In terms of the sugar-fat combination, naltrexone had no effect on palatable food intake at 1 h (F(2,29)=1.84, p=n.s.) or 12 h (F(2,29)=1.27, p=n.s.). Baclofen significantly decreased intake at 1 h (F(2,29)=9.69, p<0.01) at both doses tested (p<0.01). At 12 h, baclofen suppressed intake (F(2,29)=4.25, p<0.05), with the strongest effect seen following the higher dose (p<0.05). Lastly, there was an effect of the naltrexone and baclofen combination on sugar-fat intake at 1 h (F(2,29)=13.29, p<0.0001), with the strongest suppression seen at the higher dose (p<0.01), but no effect was observed at 12 h (F(2,29)=0.82, p=n.s.).
There was no effect of naltrexone (F(2,29)=3.31, p=n.s.; Table 6) or baclofen (F(2,29)=1.07, p>0.05) on standard chow intake in the sugar group at 1 h. However, at 12 h, naltrexone (F(2,29)=6.18, p<0.01) and baclofen (F(2,28)=4.56, p<0.05) both stimulated chow intake. The combination of naltrexone and baclofen had a significant effect on standard chow intake in the sugar group at 1 h (F(2,29)=5.34, p<0.05), with the high dose reducing intake compared to the low dose (p<0.01). At 12 h (F(2,28)=9.32, p<0.01), the combination stimulated intake of standard rodent chow at both drug doses (p<0.01, for each) compared to saline.
There was no effect of naltrexone or baclofen alone on standard chow intake in the fat group at 1 h (naltrexone: F(2,29)=2.01, p=n.s.; baclofen F(2,29)=0.44, p>0.05 or 12 h (naltrexone: F(2,29)=0.28, p=n.s.; baclofen: F(2,29)=0.27, p>0.05; Table 7). There was, however, an effect of the combination of naltrexone and baclofen 1 h (F(2,29)=10.92, p<0.0001), with less chow intake at the high dose compared to the other two groups ((saline: p<0.05) and low dose: p<0.0001). This effect did not persist, as no significant effect was seen at 12 h (F(2,29)=0.47, p=n.s.).
There was no effect of naltrexone on chow intake in the Binge Sugar-Fat group at 1 h (F(2,29)=0.65, p=n.s.) or at 12 h (F(2,29)=0.85, p=n.s.). Baclofen had a significant effect at 1 h (F(2,29)=3.58, p<0.05), with less chow intake at the high dose compared to the low dose (p<0.05), but not at 12 h (F(2,28)=0.05, p=n.s.). There was no effect of the naltrexone and baclofen combination 1 h (F(2,29)=1.07, p=n.s.) or 12 h (F(2,29)=0.46, p=n.s.).
Naltrexone significantly increased total caloric intake in the Sugar group at 1 h (F(2,29)=4.53, p<0.05; low dose compared to saline p<0.05)). However, at 12 h, differences were no longer evident (F(2,27)=3.15, p=n.s.). Baclofen had no effect on total caloric intake in the sugar group at 1 h (F(2,29)=1.63, p=n.s.) or 12 h (F(2,26)=3.22, p=n.s.). The combination of naltrexone and baclofen, however, did significantly reduce total caloric intake 1 h (F(2,29)=8.11, p<0.01; high dose (P<0.01), An effect was still apparent at 12 h (F(2,26)=6.52, p<0.01), but this time, caloric intake was increased in rats given both the low (p<0.01) and high dose (p<0.05), of the drug.
In the fat group, naltrexone had no effect on total caloric intake at 1 h (F(2,29)=3.25, p=n.s.) or 12 h (F(2, 29)=1.13, p=n.s.). Baclofen, however, significantly reduced total caloric intake at 1 h (F(2,29)=6.73, p<0.01) and 12 h (F(2,29)=4.96, 9 p<0.05), at the high dose, at each time point (p<0.05). Likewise, the combination of naltrexone and baclofen reduced total caloric intake at 1 h (F(2,29)=22.07, p<0.0001) and 12 h (F(2,29)=8.02, p<0.01), at the high dose at each time point (p<0.05).
In the Sugar-Fat group, naltrexone had no effect on total caloric intake at 1 h (F(2,29)=2.17, p=n.s.) or 12 h (F(2, 27)=1.16, p=n.s.). Conversely, baclofen reduced total caloric intake in the sugar-fat group at 1 h (F(2,29)=15.02, p<0.0001), at the high dose (p<0.01), but this effect was not apparent at 12 h (F(2,27)=2.435, p=n.s.). Likewise, the combination of naltrexone and baclofen reduced total caloric intake at 1 h (F(2,29)=13.46, p<0.0001), with less intake at the high dose (p<0.01), but this effect was not seen at 12 h (F(2,27)=0.76, p=n.s.).
4.4 ± 0.7a
2.6 ± 0.4a
17.9 ± 2.4d
18.5 ± 2.3g
23.5 ± 3.9j
24.9 ± 1.9n
34.8 ± 3.1i
23.0 ± 1.8d
15.7 ± 1.7d
11.3 ± 1.3g
13.1 ± 0.8h
11.3 ± 1.7i
78.6 ± 4.7b
17.0 ± 3.0e,f
96.6 ± 9.6 g,j
67.7 ± 9.9g
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/560,356, filed Nov. 16, 2011, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables and nucleic acid sequences.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2012/065486 | 11/16/2012 | WO | 00 | 5/15/2014 |
| Number | Date | Country | |
|---|---|---|---|
| 61560356 | Nov 2011 | US |
